Science
Mechanism of Action
Methyl Travoprost is absorbed and subsequently hydrolyzed by esterases, particularly in the cornea, to its biologically active form, travoprost free acid. This active metabolite functions as a selective FP prostanoid receptor agonist. On skin and periorbital tissues, this agonistic activity leads to an increase in melanin content within melanocytes, resulting in hyperpigmentation. Additionally, it is associated with observable alterations in vellus hair and eyelashes, including increased length, thickness, number, and pigmentation, alongside potential changes in growth direction.
Research
Clinical Evidence
Medium confidence0.004%
Key findings
- 01 Clinical trials at 0.0015% and 0.004% concentrations primarily demonstrate significant efficacy in reducing intraocular pressure by 7 to 9 mmHg in patients with open-angle glaucoma or ocular hypertension. While direct clinical studies for its cosmetic efficacy on skin are not provided in detail, its well-documented mechanism includes reports of increased pigmentation and stimulation of eyelash and vellus hair growth, observed as a side effect in ophthalmic applications. The 0.004% concentration typically showed slightly greater efficacy in IOP reduction compared to 0.0015%.
Transparency
Dusting Analysis
Methyl Travoprost is a highly potent, FDA-approved prescription drug. Its significant biological effects, including changes in pigmentation and hair growth, are observed at very low concentrations, with 0.004% being the maximum concentration for its approved drug use. Exceeding this pharmaceutical concentration in cosmetic applications presents a substantial risk of pronounced and potentially permanent side effects, making any formulation above this threshold a significant red flag for safety and regulatory compliance.
The Formula
Formulation
Stability
Methyl Travoprost is typically formulated in sterile, buffered aqueous solutions, despite the raw substance being practically insoluble in water. Optimal storage for formulated products is recommended between 2°C and 25°C to maintain stability.
Conflicts
- Benzalkonium chloride (BAK) as a preservative is noted to cause significant goblet cell loss on the ocular surface; polyquaternium-1 (PQ) preserved solutions are preferred. This suggests potential for irritation with BAK in cosmetic formulations.
- Concomitant application with other potent topical active ingredients should be considered with caution, as ophthalmic drug products typically require at least 5 minutes separation due to potential interactions.
Safety
Safety Profile
Methyl Travoprost is an FDA-approved prescription drug primarily for reducing elevated intraocular pressure. Its evaluation for cosmetic use by the CIR Panel is ongoing due to concerns raised by the SCCS. Ophthalmic use is associated with a potential for permanent increased brown pigmentation of the iris, as well as reversible pigmentation of the periorbital tissue and eyelashes. It is strongly not recommended for use in pregnant or breastfeeding women due to potential risks, and contraindications include pediatric patients under 16 years of age, primarily due to pigmentation concerns.
Your Skin
Skin Compatibility
Our Assessment
Verdict
While demonstrated to be effective at very low concentrations for highly specific effects like hair growth stimulation and pigmentation enhancement, Methyl Travoprost carries significant safety risks, including potential permanent changes, and its cosmetic use remains under regulatory scrutiny, rendering it questionable for general skincare formulations.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources